شنبه 1 دی 1403
[Archive]
دوره 29، شماره 137 - ( 7-1400 )
جلد 29 شماره 137 صفحات 338-331 |
برگشت به فهرست نسخه ها
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Soleimani S, Shahsavandi S. Comparative Evaluation of Mx and Alum as Bio and Conventional Adjuvants in Inducing Immune Responses by Influenza DNA Vaccine. J Adv Med Biomed Res 2021; 29 (137) :331-338
URL: http://journal.zums.ac.ir/article-1-6257-fa.html
URL: http://journal.zums.ac.ir/article-1-6257-fa.html
Comparative Evaluation of Mx and Alum as Bio and Conventional Adjuvants in Inducing Immune Responses by Influenza DNA Vaccine. Journal of Advances in Medical and Biomedical Research. 1400; 29 (137) :331-338
چکیده: (118326 مشاهده)
Background & Objective: DNA vaccines as a new generation of vaccines require adjuvant to improve vaccine immunogenicity; adjuvants can also increase the DNA vaccine efficacy. In this study, the effects of the host’s interferon-inducible Mx protein as bio adjuvant and conventional alum adjuvant were evaluated.
Materials & Methods: The BALB/c mice were immunized by different prime-boost strategies of the alum and Mx adjuvanted-HA2 DNA vaccine; they were challenged with the specific influenza virus. The potency and safety were evaluated. Humoral immune response was assayed by haemagglutination and virus neutralization tests. The induction of cell-mediated immune responses was determined using an MTT assay. The safety of vaccine regarding side effects occurrence was assessed by observation and histopathologic evaluation.
Results: Mx as a host defense peptide was able to increase the immune response against influenza better than alum adjuvant (p<0.01). By HA2 and Mx in prime and boost strategy, the highest level of specific antibodies developed; they are capable of inducing cell-mediated immune responses. Results indicated that Mx in the DNA vaccine could induce stronger immune responses without any side effects; but alum had some local and general reactions.
Conclusion: The Mx could effectively enhance immune responses; it has the potential to enhance the vaccine immunogenicity.
نوع مطالعه: مقاله پژوهشی |
موضوع مقاله:
Medical Biology
دریافت: 1399/9/24 | پذیرش: 1400/3/22 | انتشار: 1400/5/10
دریافت: 1399/9/24 | پذیرش: 1400/3/22 | انتشار: 1400/5/10
فهرست منابع
1. Lee LYY, Izzard L, Hurt AC. A review of DNA vaccines against influenza. Front Immunol. 2018;9:1568 [DOI:10.3389/fimmu.2018.01568]
2. Yao Y, Wang H, Chen J, et al. Protection against homo and hetero-subtypic influenza A virus by optimized M2e DNA vaccine. Emerg Microb Infect. 2019;8(1):45-54. [DOI:10.1080/22221751.2018.1558962]
3. Soleimani S, Madadgar O. Improvment influenza HA2 DNA vaccine cellular and humoral immune responses with Mx bio adjuvant. Biologicals. 2017;46:6-10. [DOI:10.1016/j.biologicals.2016.11.004]
4. Kalenik BM, Góra-Sochacka A, Stachyra A, et al. Response to a DNA vaccine against the H5N1 virus depending on the chicken line and number of doses. Virol J. 2020;17(1):66. [DOI:10.1186/s12985-020-01335-9]
5. Pandey A SN, Mittal SK. . Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses. Human Vac Immunother 2010;6:178-88. [DOI:10.4161/hv.6.2.9899]
6. Soleimani S, Madadgar O. Induction of heterologous immunity against current influenza serotypes by HA2 sub unit DNA vaccine Tehran Univ Med J. 2016;74(8):545-53.
7. Fox CB KR, Barnes L, Dowling QM, Vedvick TS. . Working together: interactions between vaccine antigens and adjutants. . Therap Adv Vac. 2013;1:7-20. [DOI:10.1177/2051013613480144]
8. Fan X HA, Chen Z, Doyle T, et al.Targeting the HA2 subunit of influenza A virus hemagglutinin via CD40L provides universal protection against diverse subtypes. Mucos Immunol. 2015;8:211-20. [DOI:10.1038/mi.2014.59]
9. Yu J, Lin Y, Chen C, Fang C. Aluminum salts as an adjuvant for pre-pandemic influenza vaccines: a meta-analysis. Sci Report. 2018:1-7.
10. Apostólico Jde SL, Coirada VA, Boscardin FC, Rosa SB. DS Adjuvants: classification, modus operandi, and licensing. J Immunol Res. 2016:1-16. [DOI:10.1155/2016/1459394]
11. Yu-Ju L, Ying-Ying L, Wen-Chi H,et al. Oil-in-water emulsion adjuvants for pediatric influenza vaccines: a systematic review and meta-analysis. Nature Comm. 2020:1-11. [DOI:10.1038/s41467-019-14230-x]
12. Kobiyama K, Aoshi T, Tozuka M, Takeshita F, Coban C, Ishii KJ. Innate immune signaling by and genetic adjutants for DNA vaccination. Vaccines 2013;1:278-92. [DOI:10.3390/vaccines1030278]
13. Liniger M SA, Ruggli N. MDA5 can be exploited as efficacious genetic adjuvant for DNA vaccination against lethal H5N1 influenza virus infection in chickens. PLoS ONE. 2012;7:e49952. [DOI:10.1371/journal.pone.0049952]
14. Wang W SM. Selection of adjuvants for enhanced vaccine potency. World J Vac. 2011;1:33. [DOI:10.4236/wjv.2011.12007]
15. Soleimani S, Maddadgar O, Mahravani H, Lotfi M. Mx bio adjuvant for enhancing immune responses against influenza virus. Tehran Univ Med J. 2015;73(3):192-201.
16. Hung JT, Lin WD, Jan JT, et al.Potent adjuvant effects of novel NKT stimulatory glycolipids on hemagglutinin based DNA vaccine for H5N1 influenza virus. Antiviral Res. 2014;107:110-8. [DOI:10.1016/j.antiviral.2014.04.007]
17. Katz J HK, Veguilla V, Zhong W,et al. Serum cross-reactive antibody response to a novel influenza a (H1N1) virus after vaccination with seasonal influenza vaccine morbid. Mort Week Report. 2009;58:521-4.
18. Wibawa H, Waluyati DE, Usman TB,et al. Comparison of serological assays for detecting antibodies in ducks exposed to H5 subtype avian influenza virus. BMC Vet Res 2012;8:117. [DOI:10.1186/1746-6148-8-117]
19. Jamali A, Bamdad T, Hashemi H, Mahboudi F, Kheiri MT. A DNA vaccine-encoded nucleoprotein of influenza virus fails to induce cellular immune responses in a diabetic mouse model. Clin Vac Immunol. 2010;17:683-7. [DOI:10.1128/CVI.00445-09]
20. Riss TL MR, Niles AL, Benink HA, Worzella TJ, Minor L. Assay Guidance Manual. Cell Viability Assays. Eli Lilly Company and the national center for advancing translational sciences 2013:210-30.
21. Fischer AH JK, Rose J, Zeller R. Hematoxylin and eosin staining of tissue and cell sections, "preparation of cells and tissues for fluorescence microscopy,", in Basic Methods in Microscopy (eds. Spector and Goldman). Cold Spring Harbor Laboratory Press, NY, USA 2006:Chapter 4.
22. Zhang H, Compans RW, Wang BZ. Universal influenza vaccines, a dream to be realized soon. Viruses 2014;6:1974-91. [DOI:10.3390/v6051974]
23. Khanna M, Kumar B, Rajput R. Protective immunity based on the conserved hemagglutinin stalk domain and its prospects for universal influenza vaccine development. . Bio Med Res Int. 2014:1-7. [DOI:10.1155/2014/546274]
24. Bragstad K, Hansen MS, Nielsen J, Fomsgaard A. A poly valent influenza A DNA vaccine induces heterologous immunity and protects pigs against pandemic A (H1N1) Pdmo9 virusinfection. Vaccine. 2013;31:2281-8. [DOI:10.1016/j.vaccine.2013.02.061]
25. Dai J, Wang B, Kuang Y, et al. A novel DNA vaccine expressing the Ag85A-HA2 fusion protein provides protection against influenza A virus and Staphylococcus aureus. . Virol J 2013;10:40. [DOI:10.1186/1743-422X-10-40]
26. Steel J, Wang TT, Yondola M, et al.Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio. 2010;1:e00018-10. [DOI:10.1128/mBio.00018-10]
27. Shan S, Fenwick S, Ellis T, et al. Evaluation of different chemical adjuvants on an avian influenza H6 DNA vaccine in chickens. Avian Pathol. 2016;45(6):649-56. [DOI:10.1080/03079457.2016.1195488]
28. Soleimani S, Madadgar O, Mahravani H, Lotfi M. In silico analysis of HA2/Mx chimera peptide for developing an adjuvanted vaccine to induce immune responses against influenza viruses. . Adv Pharmaceut Bullet. 2015;5:629-36. [DOI:10.15171/apb.2015.085]
29. Kunzler C, Souza D, Sandbulte M, Lopes S. The type of adjuvant in whole inactivated influenza a virus vaccines impacts vaccine-associated enhanced respiratory disease. Vaccine. 2018;36(41):6103-10. [DOI:10.1016/j.vaccine.2018.08.072]
30. HogenEsch H. Mechanism of immunopotentiation and safety of aluminum adjuvants. Front Immunol. 2013;3:1-13. [DOI:10.3389/fimmu.2012.00406]
31. Marrack P, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol. 2009;9(4):287-93. [DOI:10.1038/nri2510]
32. Leslie M. Solution to vaccine mystery starts to crystallize. Science. 2013;341(6141):26-7. [DOI:10.1126/science.341.6141.26]
33. Singh M, Kazzaz J , Chesko J, et al . A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. Vaccine. 2006;24:1680-6. [DOI:10.1016/j.vaccine.2005.09.046]
34. Treaner JJ. Influenza virus. In: Mandell GL BJ, Dolen R. . Principles and practice of infectious diseases. . 6 th edn Churchill living stone, Philadelphia PA 2005:2070-1.
35. Riedl K RR, Gabain AV, Nagy E, Lingnau K. The novel adjuvant IC31® strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult [36] and aged mice . Vaccine 2008;26:3461-8. [DOI:10.1016/j.vaccine.2008.04.029]
36. Moser C, Kaeser M, Weydemann U, Amacker M. Influenza virosomes as vaccine adjuvant and carrier system. . Exp Rev Vac. 2013;12:779-91. [DOI:10.1586/14760584.2013.811195]
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
